Advances in the molecular understanding of facioscapulohumeral muscular dystrophy
(FSHD) have revealed that FSHD results from epigenetic de-repression of the DUX4 gene in …

A reliable model of a disease pathomechanism is the first step to develop targeted treatment.
In facioscapulohumeral muscular dystrophy (FSHD), the third most common muscular …

Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common muscular
dystrophies. Over the last decade, a consensus was reached regarding the underlying …

Facioscapulohumeral muscular dystrophy (FSHD) is a debilitating muscular dystrophy with a
variable age of onset, severity, and progression. While there is still no cure for this disease …

Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common forms of
muscular dystrophy with a distinctive pattern of skeletal muscle weakness and a wide …

Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common types of
muscular dystrophy, affecting roughly one in 8000 individuals. The complex underlying …

Whilst a disease-modifying treatment for Facioscapulohumeral muscular dystrophy (FSHD)
does not exist currently, recent advances in complex molecular pathophysiology studies of …

Facioscapulohumeral dystrophy (FSHD) is the third most prevalent muscular dystrophy. A
progressive disease, it presents clinically as weakness and wasting of the face, shoulder …

Background Facioscapulohumeral muscular dystrophy (FSHD) is a dominantly-inherited
progressive muscular dystrophy caused by de-repression of the DUX4 gene, which causes …

Facioscapulohumeral muscular dystrophy (FSHD) is a common genetic disease of the
skeletal muscle with a characteristic pattern of weakness. Facioscapulohumeral muscular …